Analysis of Number Needed to Treat and Cost of Platelet Glycoprotein IIb/IIIa Inhibitors in Percutaneous Coronary Interventions and Acute Coronary Syndromes

Publisher Website
Google Scholar
Abstract
This retrospective review and analysis of pivotal clinical trials compared acquisition costs and outcomes of platelet glycoprotein IIb/IIIa inhibitors. Absolute reduction in the number of deaths and nonfatal myocardial infarctions at 30 days, number of patients that need to be treated to prevent one event, and drug costs expended to prevent one event were assessed. In patients undergoing percutaneous coronary intervention (PCI), abciximab is the better value, especially in high‐risk patients. In those with unstable angina and non‐Q wave myocardial infarction, costs of eptifibatide and tirofiban were not significantly different, but the cost of tirofiban was more variable. These agents have the potential to be cost‐effective if administered to populations at high risk for adverse outcomes of acute coronary syndromes or PCI. Prospective methods to identify these high‐risk patients are being developed.

This publication has 15 references indexed in Scilit: